1. Home
  2. LULU vs GMAB Comparison

LULU vs GMAB Comparison

Compare LULU & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo lululemon athletica inc.

LULU

lululemon athletica inc.

HOLD

Current Price

$138.17

Market Cap

16.5B

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.55

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LULU
GMAB
Founded
1998
1999
Country
Canada
Denmark
Employees
N/A
3029
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5B
16.9B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
LULU
GMAB
Price
$138.17
$26.55
Analyst Decision
Hold
Strong Buy
Analyst Count
25
8
Target Price
$190.26
$39.56
AVG Volume (30 Days)
2.4M
1.5M
Earning Date
06-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
13.26
N/A
Revenue
$11,102,600,000.00
N/A
Revenue This Year
$5.52
$17.85
Revenue Next Year
$4.68
$16.04
P/E Ratio
$10.38
$1.90
Revenue Growth
4.86
N/A
52 Week Low
$136.91
$18.89
52 Week High
$340.25
$35.43

Technical Indicators

Market Signals
Indicator
LULU
GMAB
Relative Strength Index (RSI) 32.38 42.27
Support Level N/A $24.95
Resistance Level $170.94 $29.64
Average True Range (ATR) 5.24 0.54
MACD -2.23 -0.18
Stochastic Oscillator 4.74 21.29

Price Performance

Historical Comparison
LULU
GMAB

About LULU lululemon athletica inc.

Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: